Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Chasing a 100 times return might not be a great idea. But there are lessons to be taken from past winners of this magnitude.

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Activist hedge fund Starboard Value has increased its stake in Salesforce ($CRM) by nearly 50% during the second quarter, according to a recent ...

Serve your customers well, and the profits will follow, according to a new book. It rarely works the other way around, says ...

Even as the FTSE 100 reaches new all-time highs, there remains plenty of explosive growth opportunities to capitalise on. And ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS guidance. See more on PFE stock here.

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...

Pfizer ( PFE 0.22%) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.